quinacrine has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 23 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE)." | 5.46 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. ( Alves, P; Bashir, MM; Feng, R; Werth, VP; Wysocka, M; Zeidi, M, 2017) |
| "Cutaneous lupus erythematosus has a variety of clinical presentations, but treatment is similar for the different forms." | 2.41 | Current treatment of cutaneous lupus erythematosus. ( Werth, V, 2001) |
| "Although antimalarials are the primary treatment for cutaneous lupus erythematosus, not all patients are equally responsive." | 1.51 | Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. ( Kim, HJ; Werth, VP; Zeidi, M, 2019) |
| "Methods Mepacrine was added to 46 systemic lupus erythematosus patients unresponsive to treatment with the following drug combinations: hydroxychloroquine + prednisone + immunosuppressive drugs ( n = 24), hydroxychloroquine + prednisone ( n = 16), hydroxychloroquine + prednisone + retinoids ( n = 2), hydroxychloroquine alone ( n = 1), hydroxychloroquine + one immunosuppressive drug ( n = 1), hydroxychloroquine + prednisone + one immunosuppressive drug + belimumab ( n = 1) or hydroxychloroquine + prednisone + belimumab ( n = 1)." | 1.48 | Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity. ( Agesta, N; Martinez-Zapico, A; Ortego-Centeno, N; Porta, S; Ríos, R; Ruiz-Irastorza, G; Ugarte, A, 2018) |
| "Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE)." | 1.46 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. ( Alves, P; Bashir, MM; Feng, R; Werth, VP; Wysocka, M; Zeidi, M, 2017) |
| "A total of 218 individuals with CLE or systemic lupus erythematosus and lupus nonspecific skin disease seen between January 5, 2007, and July 30, 2010." | 1.38 | Impact of smoking in cutaneous lupus erythematosus. ( Chang, AY; Feng, R; Foering, KP; Okawa, J; Piette, EW; Ten Have, TR; Werth, VP, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.35) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Zeidi, M | 3 |
| Chen, KL | 1 |
| Patel, J | 2 |
| Desai, K | 1 |
| Kim, HJ | 2 |
| Chakka, S | 1 |
| Lim, R | 1 |
| Werth, VP | 8 |
| Vazquez, T | 1 |
| Chin, F | 1 |
| Keyes, E | 1 |
| Yan, D | 2 |
| Diaz, D | 1 |
| Grinnell, M | 1 |
| Sharma, M | 1 |
| Li, Y | 1 |
| Feng, R | 3 |
| Sprow, G | 1 |
| Dan, J | 1 |
| Borucki, R | 1 |
| Sontheimer, RD | 2 |
| Mittal, L | 1 |
| Alves, P | 1 |
| Bashir, MM | 1 |
| Wysocka, M | 1 |
| Ugarte, A | 1 |
| Porta, S | 1 |
| Ríos, R | 1 |
| Martinez-Zapico, A | 1 |
| Ortego-Centeno, N | 1 |
| Agesta, N | 1 |
| Ruiz-Irastorza, G | 1 |
| Benoit, S | 1 |
| Goebeler, M | 1 |
| Stannard, JN | 1 |
| Kahlenberg, JM | 1 |
| García-Montero, P | 1 |
| Del Boz, J | 1 |
| Millán-Cayetano, JF | 1 |
| de Troya-Martín, M | 1 |
| Wuyts, L | 1 |
| Dandelooy, J | 1 |
| Siozopolou, V | 1 |
| Lambert, J | 1 |
| Aerts, O | 1 |
| Cavazzana, I | 1 |
| Sala, R | 1 |
| Bazzani, C | 1 |
| Ceribelli, A | 1 |
| Zane, C | 1 |
| Cattaneo, R | 1 |
| Tincani, A | 1 |
| Calzavara-Pinton, PG | 1 |
| Franceschini, F | 1 |
| Chang, AY | 2 |
| Piette, EW | 2 |
| Foering, KP | 2 |
| Tenhave, TR | 1 |
| Okawa, J | 2 |
| Ten Have, TR | 1 |
| Callen, JP | 1 |
| López-Jornet, P | 1 |
| Pons-Fuster, A | 1 |
| Vidal, D | 1 |
| Altés, J | 1 |
| Smandia, JA | 1 |
| BETTLEY, FR | 1 |
| Martin, TJ | 1 |
| Sharp, I | 1 |
| Geraminejad, P | 1 |
| Stone, MS | 1 |
| Lipsker, D | 1 |
| Piette, JC | 1 |
| Cacoub, P | 1 |
| Godeau, P | 1 |
| Frances, C | 1 |
| Feldmann, R | 1 |
| Salomon, D | 1 |
| Saurat, JH | 1 |
| Werth, V | 1 |
3 reviews available for quinacrine and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.
Topics: Antimalarials; Humans; Lupus Erythematosus, Cutaneous; Pharmaceutical Preparations; Quinacrine | 2020 |
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2016 |
Current treatment of cutaneous lupus erythematosus.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Antimalarials; Aspirin; Diagnosis, Differen | 2001 |
20 other studies available for quinacrine and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antimalarials; Female; Fluorescent Antibody T | 2022 |
Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials.
Topics: Antimalarials; Granzymes; Humans; Hydroxychloroquine; Immunosuppressive Agents; Interferon Regulator | 2022 |
The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
Topics: Academic Medical Centers; Administration, Oral; Adult; Aged; Antimalarials; Databases, Factual; Derm | 2017 |
Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.
Topics: Antimalarials; Cells, Cultured; Dendritic Cells; Dermatomyositis; Drug Interactions; Humans; Hydroxy | 2017 |
Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Topics: Adult; Antimalarials; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Immunosuppressi | 2018 |
Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
Topics: Adult; Antimalarials; Dendritic Cells; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cuta | 2019 |
Mepacrine in Recalcitrant Cutaneous Lupus Erythematosus: Old-fashioned or Still Useful?
Topics: Adrenal Cortex Hormones; Antimalarials; Cohort Studies; Dose-Response Relationship, Drug; Drug Admin | 2015 |
Quinacrine: A Treatment Option That Should Not Be Overlooked.
Topics: Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Quinacrine | 2016 |
Mepacrine as successful monotherapy for refractory Jessner-Kanof disease: still an important drug in the dermatologic armamentarium.
Topics: Adult; Enzyme Inhibitors; Epidermis; Female; Fluorescent Antibody Technique, Direct; Humans; Lupus E | 2017 |
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Topics: Adult; Antimalarials; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2009 |
Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
Topics: Adolescent; Adult; Aged; Antimalarials; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up | 2011 |
Impact of smoking in cutaneous lupus erythematosus.
Topics: Adult; Antimalarials; Cohort Studies; Comorbidity; Cross-Sectional Studies; Drug Therapy, Combinatio | 2012 |
Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
Topics: Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Male; Quinacrine | 2011 |
Pigmented oral mucosa due to quinacrine.
Topics: Antimalarials; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, Cutaneous; Melanoma; Mi | 2011 |
Yellow skin discoloration induced by quinacrine in a patient with cutaneous lupus erythematosus.
Topics: Aged; Drug Eruptions; Female; Humans; Lupus Erythematosus, Cutaneous; Pigmentation Disorders; Quinac | 2013 |
CHILBLAIN LUPUS ERYTHEMATOSUS.
Topics: Chilblains; Chloroquine; Fluocinolone Acetonide; Frostbite; Humans; Hydroxychloroquine; Hypothyroidi | 1964 |
Oral mucosal pigmentation secondary to treatment with mepacrine, with sparing of the denture bearing area.
Topics: Denture, Partial; Dermatologic Agents; Female; Humans; Lupus Erythematosus, Cutaneous; Melanosis; Mi | 2004 |
Antimalarial lichenoid tissue reactions in patients with pre-existing lupus erythematosus.
Topics: Antimalarials; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lichenoid Eruptions; Lup | 2004 |
Chloroquine-quinacrine association in resistant cutaneous lupus.
Topics: Adult; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Lupus Erythematosus, Cutaneo | 1995 |
The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Topics: Adult; Aged; Chloroquine; Drug Combinations; Drug Tolerance; Female; Humans; Hydroxychloroquine; Lup | 1994 |